GlassScriptPhysician profile
Danelle Joy Saxe
NPI 1609837004
$9,854.33
in general payments reported to CMS, 2019-2025
38 companies · $2,343 in 2025
The $2,343 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,226 · 2022: $1,925 · 2023: $1,880 · 2024: $2,480 · 2025: $2,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,702.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,714.48 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,323.26 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,300.32 | 2021-2025 | |
| Lilly USA, LLC | $961.76 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $547.57 | 2021-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.76 | 2021-2024 | Tradjenta, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $471.52 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $404.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $331.93 | 2021-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $330.39 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $326.24 | 2022-2025 | |
| Pfizer INC. | $278.05 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $184.04 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $169.34 | 2021-2025 | Arexvy, Bexsero, Shingrix |
| Merck Sharp & Dohme LLC | $148.64 | 2021-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danelle Saxe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.